Several analysts have recently updated their ratings and price targets for Deciphera Pharmaceuticals (NASDAQ: DCPH):
- 9/27/2022 – Deciphera Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $11.00 to $18.00. They now have a "hold" rating on the stock.
- 9/12/2022 – Deciphera Pharmaceuticals had its price target raised by analysts at SVB Leerink LLC from $21.00 to $25.00. They now have an "outperform" rating on the stock.
- 9/12/2022 – Deciphera Pharmaceuticals had its price target raised by analysts at HC Wainwright from $20.00 to $25.00. They now have a "buy" rating on the stock.
- 9/11/2022 – Deciphera Pharmaceuticals had its price target raised by analysts at Piper Sandler from $13.00 to $18.00.
- 8/29/2022 – Deciphera Pharmaceuticals is now covered by analysts at Cowen Inc.. They set an "outperform" rating and a $25.00 price target on the stock.
- 8/29/2022 – Deciphera Pharmaceuticals is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $25.00 price target on the stock.
- 8/5/2022 – Deciphera Pharmaceuticals had its price target raised by analysts at SVB Leerink LLC from $15.00 to $21.00. They now have an "outperform" rating on the stock.
- 8/5/2022 – Deciphera Pharmaceuticals was upgraded by analysts at JMP Securities from a "market perform" rating to an "outperform" rating. They now have a $23.00 price target on the stock.
- 8/5/2022 – Deciphera Pharmaceuticals had its price target raised by analysts at HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
Deciphera Pharmaceuticals Trading Down 3.5 %
Shares of DCPH opened at $17.62 on Friday. Deciphera Pharmaceuticals, Inc. has a 1 year low of $6.51 and a 1 year high of $20.88. The stock has a market cap of $1.18 billion, a P/E ratio of -4.12 and a beta of 1.00. The stock's 50-day moving average price is $16.33 and its two-hundred day moving average price is $12.91.
Get Deciphera Pharmaceuticals Inc alerts:Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.05. Deciphera Pharmaceuticals had a negative return on equity of 74.37% and a negative net margin of 231.99%. The business had revenue of $32.49 million for the quarter, compared to analysts' expectations of $30.11 million. During the same quarter in the previous year, the business posted ($1.21) EPS. Deciphera Pharmaceuticals's revenue for the quarter was up 37.8% on a year-over-year basis. As a group, equities analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.5 EPS for the current year.
Hedge Funds Weigh In On Deciphera Pharmaceuticals
Several institutional investors have recently modified their holdings of DCPH. Goldman Sachs Group Inc. raised its position in Deciphera Pharmaceuticals by 739.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,635,510 shares of the company's stock valued at $35,519,000 after buying an additional 3,202,527 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at approximately $10,772,000. Federated Hermes Inc. raised its position in Deciphera Pharmaceuticals by 125.5% in the 1st quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company's stock valued at $18,161,000 after buying an additional 1,090,368 shares during the last quarter. BlackRock Inc. increased its position in shares of Deciphera Pharmaceuticals by 27.6% during the 1st quarter. BlackRock Inc. now owns 4,845,376 shares of the company's stock worth $44,917,000 after purchasing an additional 1,047,807 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C increased its position in shares of Deciphera Pharmaceuticals by 12.0% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 6,250,964 shares of the company's stock worth $82,200,000 after purchasing an additional 670,508 shares during the last quarter. Institutional investors own 72.29% of the company's stock.Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
See Also
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- Humana Proves Vertically Integrated Healthcare Works
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- What Cintas Can Teach Investors About This Bear Market?
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
Receive News & Ratings for Deciphera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.